VYNE Therapeutics
VYNE
64 hedge funds and large institutions have $20.1M invested in VYNE Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 16 closing their positions.
338% more call options, than puts
Call options by funds: $140K | Put options by funds: $32K
0.41% less ownership
Funds ownership: 1.97% → 1.56% (-0.41%)
11% less funds holding
Funds holding: 72 → 64 (-8)
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
69% less capital invested
Capital invested by funds: $64M → $20.1M (-$43.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.01M |
| 2 |
VF
Virtu Financial
New York
|
+$233K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$199K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$119K |
| 5 |
Two Sigma Investments
New York
|
+$73.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.42M |
| 2 |
DAM
Deltec Asset Management
New York
|
-$768K |
| 3 |
E
Ergoteles
New York
|
-$557K |
| 4 |
Millennium Management
New York
|
-$532K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$426K |
VYNE Hedge Fund Activity: Q3 2021 in Review
64 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2021, worth a combined $20.1M — down 69% from $64M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VYNE and 8 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 18 added.
The largest buyer was Renaissance Technologies, adding an estimated $2.01M. The largest seller was Perceptive Advisors, cutting an estimated $7.42M.
- 64 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2021, down from 72 in Q2 2021.
- Funds reported $20.1M of VYNE Therapeutics stock for Q3 2021, down 69% quarter-over-quarter.
- 8 funds opened new VYNE Therapeutics positions in Q3 2021 and 16 closed out, a net change of -8 holders.
- The largest VYNE Therapeutics buyer in Q3 2021 was Renaissance Technologies, an estimated $2.01M added.
- The largest VYNE Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $7.42M sold.
Based on aggregated 13F filings for Q3 2021.